

December 20, 2018
Ohara Pharmaceutical Co., Ltd.

Novel development drug OP-724 (PRI-724) for the treatment of cirrhosis is published on Nature Outline

Ohara Pharmaceutical Co., Ltd. (Headquarters: Koga, Shiga Prefecture, President and Representative Director: Seiji Ohara) announces that its novel OP - 724 (PRI - 724) program under development for the treatment of cirrhosis is published in Nature Outline (Issued on December 20). For further details, please see the Nature Outline site below.

URL: <https://www.nature.com/collections/ycpfrvtnhj>

PDF download link:

- ① Information on OP-724(PRI-724)
<https://www.nature.com/magazine-assets/d42473-018-00371-y/d42473-018-00371-y.pdf>
- ② Overview of liver cirrhosis
<https://www.nature.com/magazine-assets/d41586-018-07759-2/d41586-018-07759-2.pdf>

(The above URL, PDF download link will be deactivated on June 19, 2019)

On 16th October this year, the National Institute of Health R & D (Japan Medical Research and Development Organization) ("AMED") completed its review of the OP-724 practical application plan targeting cirrhosis caused by hepatitis B and C viruses and selected OP-724 as one of the products to developed under the the development category "general for practical use" for fiscal year 2018 (Heisei 30) "Medical R & D Innovation Foundation Creation Project (CiCLE)" (3rd). We will continue progress the development to deliver OP-724 to patients suffering from liver cirrhosis as soon as possible.

【About Nature Outline】

Nature Outline is a new project to explain science, technology and medicine applications with editorial articles, infographic and animation as Supplement of the international comprehensive science journal Nature.

An editorial article explaining the application of science, technology and medicine in an easy-to-understand manner is posted on the magazine of Nature, the online version contains animation content, and it is also released on YouTube.

【About OP-724】

OP-724 is a CBP/beta-catenin antagonist that inhibits the activation of the Wnt/beta-catenin signaling pathway (PRISM BioLab Co., Ltd. development code: PRI-724). OP-724 was originally developed as an anticancer drug, but a study at the Tokyo Metropolitan Institute of Medical Science using a liver cirrhosis mouse model independently developed by the institute confirmed that OP-724 has antifibrotic effects showed improvement in liver histology. The study was conducted with the support of the Acceleration Transformative research for Medical innovation (ACT-M) Basic Scheme sponsored by the AMED. An investigator-initiated phase I clinical trial was completed in patients with liver cirrhosis in Japan. The study was conducted at the Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital.

We obtained development rights to OP-724 from PRISM BioLab Co., Ltd. on May 24th of this year and are now continuing the development efforts originally led by PRISM BioLab Co., Ltd.